AbbVie Inc. (ABBV)
Only Have $500? 3 No-Brainer Stocks to Buy Right Now
Forget the old adage “it takes money to make money.
3 No-Brainer Healthcare Stocks to Buy With $1,000 Right Now
Many investors view the healthcare sector as a safe haven when the stock market is turbulent. That's understandable.
AbbVie Is Preparing To Challenge Eli Lilly And Novo Nordisk
AbbVie Inc. entered the obesity market by in-licensing GUBamy, a long-acting amylin analog, a modest but important first step to challenge Eli Lilly and Novo Nordisk. AbbVie's will pay $350 million upfront for GUBamy, with potential milestones up to $1.875 billion, and royalties on net sales. Amylin analogs like GUBamy offer promising weight loss effects (albeit not at the levels of leading incretin therapies), with potentially much better GI tolerability, lean mass preservation and cardiovascular safety.
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Worried About a Market Meltdown? 2 Dividend Stocks to Own Forever.
I often say that investing rarely has a dull moment, which is why I find it so fascinating. The beginning of 2025 certainly has been no different.
Why AbbVie (ABBV) Dipped More Than Broader Market Today
In the latest trading session, AbbVie (ABBV) closed at $213.59, marking a -1.42% move from the previous day.
AbbVie Inc. (ABBV) Leerink Partners Global Healthcare Conference (Transcript)
AbbVie Inc. (NYSE:ABBV ) Leerink Partners Global Healthcare Conference March 11, 2025 8:40 AM ET Company Participants Jeff Stewart - Executive Vice President, Chief Commercial Officer Roopal Thakkar - EVP, Research & Development, Chief Scientific Officer Scott Reents - Executive Vice President, Chief Financial Officer Rob Michael - Chief Executive Officer Conference Call Participants David Risinger - Leerink Partners David Risinger All right. Good morning, everybody.
This Top Dividend Stock Just Entered The Weight Loss Market: Is It a Buy?
It's not too often that pharmaceutical drugs become household names, but that's happening with medicines in the weight loss market. Brands such as Wegovy and Zepbound -- the leading anti-obesity therapies -- are now well known and are generating billions of dollars in annual sales.
3 Cheap Stocks to Buy With Your Tax Refund Check
The average tax refund in 2024 was $3,138, which was similar to the $3,167 it averaged the previous year. While tax refunds will vary depending on a person's individual financial situation, if you receive one, it can provide you with some extra cash you can put toward paying down debt, adding to savings, or perhaps even investing in stocks.
2 Dividend Stocks to Buy for a Lifetime of Passive Income
Dividend investors don't buy shares of companies hoping they will suspend their payouts soon. The longer a corporation maintains its dividend program, the more attractive it is to income seekers, all else being equal.
AbbVie Inc. (ABBV) TD Cowen 45th Annual Health Care Conference (Transcript)
AbbVie Inc. (NYSE:ABBV ) TD Cowen 45th Annual Health Care Conference March 5, 2025 9:10 AM ET Company Participants Scott T. Reents - Executive Vice President and Chief Financial Officer Jeffrey R.
Here's How to Play AbbVie Stock as it Enters the Obesity Space
Those who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth in 2025.
